Trials / Terminated
TerminatedNCT02187029
Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.
A Randomized, Double Blind, Third Party Open, Placebo Controlled Multi-center Study Of Efficacy, Safety And Tolerability Of Pf-06743649 In Gout Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the effect of PF-06743649 in lowering serum uric acid in subjects suffering from gout following 14 days of dosing, as well as assessing safety and tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06743649 | Daily dosing (dose level 1) tablet for 14 days |
| OTHER | Placebo | Daily dosing (tablet) for 14 days |
| DRUG | PF-06743649 | Daily dosing (dose level 2) tablet(s) for 14 days |
| OTHER | Placebo | Daily dosing (tablets) for 14 days |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2014-07-10
- Last updated
- 2016-11-11
- Results posted
- 2016-11-11
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02187029. Inclusion in this directory is not an endorsement.